Bio-Rad Laboratories (NYSE:BIO) reported first-quarter 2026 results that fell within its revenue guidance range, while management emphasized that geopolitical disruption in the Middle East and continu ...

Thank you, Regina. My name is Ruben Argueta, Bio-Rad's new Head of IR. Today, we will review the financial results for the first quarter ended March 31, 2026, and provide an update on key business ...

Q1 2026 Management View Jonathan DiVincenzo (President & COO) said Bio-Rad “reported Q1 results within our revenue guidance” while facing “several external pressures, most notably associated with the ...

Bio-Rad Laboratories lowered its 2026 revenue growth outlook to between -3% and +0.5% due to Middle East disruptions, while Amgen raised its full-year revenue and EPS guidance on strong product ...

Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported a first-quarter loss of $527.1 million, after reporting a profit in the same period a ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, announced today that it has reached an ...

Bio-Rad posted a first-quarter net loss of $527.1 million, compared with net income of $64 million a year earlier. The loss was primarily attributed to a fair-value change in its Sartorius AG ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju ...

Bio-Rad is a "picks and shovels" company in the life sciences industry, but lacks standout growth, margins, or returns, and that has been largely true for more than two decades. Recent trends in the ...

TheFly reported on April 7 that Citigroup lowered its rating on BIO from Buy to Neutral and reduced its price target from ...